<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648827</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-045-DMD</org_study_id>
    <secondary_id>2019-001767-67</secondary_id>
    <nct_id>NCT03648827</nct_id>
  </id_info>
  <brief_title>A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)</brief_title>
  <official_title>Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the ability of ataluren to increase dystrophin protein&#xD;
      levels in muscle cells of participants with nmDMD. The study will evaluate the levels of&#xD;
      dystrophin before and after 40 weeks of ataluren therapy using muscle biopsies and 2&#xD;
      validated assay methods, electrochemiluminescence (ECL) and immunohistochemistry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Dystrophin Levels at Week 40, as Measured by ECL</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>The change in levels of dystrophin from baseline in ambulatory nmDMD participants after treatment with ataluren for 40 weeks using quantitative assay, such as ECL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Dystrophin Levels/Intensity at Week 40, as Determined by a Validated Immunohistochemistry Assay</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>The change in dystrophin levels/intensity from baseline in ambulatory nmDMD participants after 40 weeks of ataluren therapy as determined by a validated immunohistochemistry assay.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Ataluren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren</intervention_name>
    <description>Ataluren will be administered as per the dose and schedule specified in the arm.</description>
    <arm_group_label>Ataluren</arm_group_label>
    <other_name>PTC124</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of signed and dated informed consent/assent document(s) indicating that the&#xD;
             participant (and/or his parent/legal guardian) has been informed of all pertinent&#xD;
             aspects of the trial.&#xD;
&#xD;
          -  Phenotypic evidence of duchenne muscular dystrophy (DMD) based on the onset of&#xD;
             characteristic clinical symptoms or signs (for example, proximal muscle weakness,&#xD;
             waddling gait, and Gowers' maneuver) and an elevated serum creatine kinase (CK).&#xD;
             Medical documentation of phenotypic evidence of DMD needs to be provided upon request&#xD;
             by the Sponsor's medical monitor.&#xD;
&#xD;
          -  Documentation of the presence of a nonsense point mutation in the dystrophin gene as&#xD;
             determined by gene sequencing. Review and approval of documentation by sponsor or&#xD;
             designee is required prior to enrollment.&#xD;
&#xD;
          -  Willing to undergo muscle biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.&#xD;
&#xD;
          -  Known contra-indication to muscle biopsy (such as bleeding or clotting disorders).&#xD;
&#xD;
          -  Prior or ongoing therapy with ataluren.&#xD;
&#xD;
          -  Known hypersensitivity to any of the ingredients or excipients of the study drug (for&#xD;
             example, refined polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C,&#xD;
             crospovidone XL10, hydroxyethyl cellulose, colloidal silica, magnesium stearate).&#xD;
&#xD;
          -  Exposure to another investigational drug within 2 months prior to start of study&#xD;
             treatment, or ongoing participation in any interventional clinical trial.&#xD;
&#xD;
          -  Requirement for daytime ventilator assistance or any use of invasive mechanical&#xD;
             ventilation via tracheostomy. Evening non-invasive mechanical ventilation such as use&#xD;
             of bilevel positive airway pressure (Bi-PAP) therapy is allowed.&#xD;
&#xD;
          -  Elevated serum creatinine or cystatin C levels at screening.&#xD;
&#xD;
          -  Prior or ongoing medical condition (for example, concomitant illness, psychiatric&#xD;
             condition, behavioral disorder), medical history, physical findings or laboratory&#xD;
             abnormality that, in the investigator's opinion, could adversely affect the safety of&#xD;
             the participant, makes it unlikely that the course of treatment or follow-up would be&#xD;
             completed, or could impair the assessment of study results.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bibbiani, MD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California (UC) Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Heath Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <disposition_first_submitted>January 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2021</disposition_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

